Overview

A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Surufatnib combined with Toripalimab compared with FOLFIRI in the treatment of advanced neuroendocrine carcinoma
Phase:
Phase 3
Details
Lead Sponsor:
Hutchison Medipharma Limited
Treatments:
Calcium
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin